As of Friday close, POINT Biopharma Global Inc.’s (NASDAQ:PNT) stock was up $0.48, moving up 6.30 percent to $8.10. The average number of shares traded per day over the past five days has been 756,380 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.89 fall in that time frame. In the last twenty days, the average volume was 609,605, while in the previous 50 days, it was 678,864.
Since last month, PNT stock retreated -11.86%. Shares of the company fell to $7.42 on 08/17/23, the lowest level in the past month. A 52-week high of $11.13 was reached on 05/15/23 after having rallying from a 52-week low of $5.59. Since the beginning of this year, PNT’s stock price has risen by 11.11% or $0.81, and marked a new high 14 times. However, the stock has declined by -27.22% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
PNT stock investors should be aware that POINT Biopharma Global Inc. (PNT) stock had its last reported insider trading activity 263 days ago on Nov 29. MCCANN JOE A., the Chief Executive Officer of the company, purchased of 2,160 shares for $6.64 on Nov 29. It resulted in a $14,342 investment by the insider. Malik Rajesh added 3,700 shares at an average price of $6.66 on Nov 28. The insider now owns 3,700 shares following the transaction. On Nov 25, Director HOGUE GERALD L. bought 3,660 shares at $6.82 apiece. The transaction was valued at $24,943.
Valuation Metrics
Right now, POINT Biopharma Global Inc. (PNT) has a P/E ratio of about 10.44. The stock’s beta is 0.19. Besides these, the trailing price-to-sales (P/S) ratio of 3.65, the price-to-book (PB) ratio of 1.81, and the price-to-cash flow ratio of 5.52 may also be considered.
Financial Health
In the recent quarter, POINT Biopharma Global Inc.’s quick ratio stood at 5.60, while its current ratio was 5.60, showing that the company is able to pay off its debt. Based on annual data, PNT earned $101.06 million in gross profit and brought in $226.58 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 19.30%. Return on equity (ROE) for the past 12 months was 26.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PNT’s revenue rose 100.0% to $9.46 million during the quarter, while net income inched up to $4.87 million. During the quarter, the company generated -$34.62 million in EBITDA. The liabilities of POINT Biopharma Global Inc. were 50.32 million at the end of its most recent quarter. The value of shareholders’ equity is $105.77 million.
Technical Picture
This quick technical analysis looks at POINT Biopharma Global Inc.’s (PNT) price momentum. With a historical volatility rate of 72.86%, the RSI 9-day stood at 40.84% on 18 August.
With respect to its five-day moving average, the current POINT Biopharma Global Inc. price is down by -9.90% percent or -$0.89. At present, PNT shares trade -11.62% below its 20-day simple moving average and +15.71% percent above its 100-day simple moving average. However, the stock is currently trading approximately -18.35% below its SMA50 and -13.18% below its SMA200.
Stochastic coefficient K was 18.38% and Stochastic coefficient D was 22.41%, while ATR was 0.51. Given the Stochastic reading of 35.98% for the 14-day period, the RSI (14) reading has been calculated as 40.84%. As of today, the MACD Oscillator reading stands at -0.55, while the 14-day reading stands at -0.70.
Analyst Ratings
POINT Biopharma Global Inc. (PNT) has been rated Buy by analysts. According to 0 brokerage firms, PNT is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate POINT Biopharma Global Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $13.00 – $27.00. Based on these forecasts, analysts predict POINT Biopharma Global Inc. (PNT) will achieve an average price target of $16.90.
